Euro Obesity Market Analysis and Reports | Spain Conference Series

Market Analysis - Euro Obesity 2020

Market Analysis

The global obesity treatments market was valued at USD 6.14 Billion in 2018 and is expected to reach USD 19.90 Billion by year 2026, at a CAGR of 16.7 %. The study covers in-depth analysis of obesity treatment options and upcoming innovations to cure obesity. Obesity is caused by increase in the size of fat cells in the body. Obesity is a serious medical condition that leads to high blood pressure, high cholesterols and heart diseases. Losses of sleep, consumption of excess junk food, physical inactiveness are major causes of obesity. The global obesity market is propelled by number of factors such as technological advancements in the medical sector, commercial easy availability of weight management treatments and various government initiative regarding overweight issues. According to world health organization (WHO), around 13% of the world’s population is characterized as “obese”. High costs, weight regain after obesity treatments are major hindrance faced by the global obesity treatment market

The global Obesity Treatment Market can expect to achieve an approximate CAGR of 16.7% during the forecast period (2017-2023), says Market Research Future (MRFR). The accelerated expansion of the obese population is fueling the prevalence of chronic diseases. Consequently, the need for effective obesity treatment for curbing the growth of chronic diseases is on the rise. The global Obesity Treatment Market can expect to achieve an approximate CAGR of 16.7% during the forecast period (2017-2023), says Market Research Future (MRFR). The accelerated expansion of the obese population is fueling the prevalence of chronic diseases. Consequently, the need for effective obesity treatment for curbing the growth of chronic diseases is on the rise.

The anti-obesity drugs market is growing steadily with the gradual growth in the number of approvals from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). North America, especially the United States, dominates this market, due to better healthcare services and high expenditure, followed by Europe. Till 2012, Xenical (orlistat) and generic phentermine were among the only approved drugs. However, the period between 2012 and 2016 saw high growth in the number of major pharmaceutical companies investing largely on clinical trials. However, there are still very less drugs in the late stage of development.

Owing to the less success rate and withdrawal among the centrally acting drugs, several of the major companies have considered the development of anti-obesity drugs as prohibitively risky and shifted the companies’ inclination toward broadening the scope of a diabetic portfolio into obesity. Since several companies have developed a strong relationship between Type 2 diabetes and obesity, it is often considered to be a low-risk strategy and minor investments in the R&D for potential anti-obesity drugs. Currently, the market is gradually growing its authority in the developing regions with the gradual approval of drugs, globally. However, it holds great potential with the aforementioned advantages, as several companies are targeting dual therapy mode for the treatment of obesity.

Importance & Scope:

Obesity is one of the most significant pathogens in the developed world. It causes or exacerbates numerous common and lethal diseases. It can markedly reduce the quality of life and it competes with smoking as the commonest cause of premature death. The prevalence of obesity has increased markedly in the last thirty years. A systematic review of 199 countries in 2008 estimated 502 million people worldwide were obese1. According to the World Health Organization, obesity has more than doubled worldwide since 1980 and more than 600 million or 13% of the adult population were obese in 2014

Obesity’ (NICE clinical guideline 43) made clinical recommendations for all managers and health professionals providing NHS care on preventing and managing overweight and obesity. The guideline aimed to ensure that obesity became a priority at both strategic and delivery levels.

The evidence base for very-low-calorie diets has expanded since the publication of the NICE guideline on obesity in 2006, and their use has increased. However, these interventions are not clearly defined, and there are concerns about safety, adherence and the sustainability of weight loss.

 

Target Audience:

  • Diabetes Educators
  • Physical Therapists
  • Industry Professionals
  • Medical Colleges
  • Health Promoters
  • Public Health Professionals
  • Pharmacists
  • Drugs & R & D Medical Devices Manufacturing Companies
  • Basic Clinical Research Scientists & Students
  • Metabolic & Bariatric Surgeons
  • Physicians
  • Integrated Health Professionals
  • Registered Dieticians & Nutritionists
  • Yoga & Fitness Professionals
  • Obesity & Endocrinology Associations and Societies
  • Business Entrepreneurs
  • BMI Training Institutes

Related Companies/Industries/Hospitals:

  • Obesity Surgery Company- London
  • The London Obesity Clinic
  • Harley Street Obesity Clinic
  • Beckenham Hospital
  • Cromwell Hospital
  • Greenwich Hospital, London
  • Harold Wood Hospital
  • Highgate Hospital
  • Highgate Private Hospital
  • Hospital of St John and St Elizabeth
  • Hospitals in Richmond upon Thames
  • King Edward VII's Hospital
  • Lister Hospital (Chelsea)
  • London Bridge Hospital
  • London Welbeck Hospital
  • North Middlesex Hospital
  • Poplar Hospital
  • Tite Street Children's Hospital
  • Portland Hospital
  • The Princess Grace Hospital
  • Priory Hospital
  • Royal Hospital for Neuro-disability
  • St. Anthony's Hospital, North Cheam
  • St Luke's Hospital for the Clergy
  • St Pancras Hospital
  • Scio House Hospital
  • Wellington Hospital, London
  • Weymouth Street Hospital

Related Associations and Societies:

  • British Obesity Society
  • World Obesity Federation
  • British Obesity & Metabolic Surgery Society
  • European Association for the Study of Obesity
  • Association for the Study of Obesity
  • International association for the study of obesity
  • World Obesity Federation
  • Global Obesity Prevention Center
  • World Health Organisation
  • World Heart Federation
  • The International Association for the Study of Obesity
  • The International Diabetes Federation
  • The International Pediatric Association
  • The International Union of Nutritional Sciences
  • The International Development Research Centre
  • Beth Israel Deaconess Medical Center,
  • Mayo Clinic & Mayo Foundation,
  • UT South-western Medical Center
  • Centre for Obesity Research and Education (CORE)

Obesity Conferences 2020 is a worldwide stage to examine and find out about Weight Management, Euro Obesity, Anti-obesity drugs, Obesity &Cancer, Genetic Obesity, Obesity in ladies, Obesity and CVS diseases, Obesity and Diabetes, Advanced medications for Obesity, Health Behavior and Environment, Basic nourishment and diet, Bariatric treatment, Scientific gatherings and meetings and the field of Obesity. Obesity and Endocrinology Meetings would talk about different themes identified with Neuro Endocrinology, Metabolic Syndromes and Anorexia, Pediatric Endocrinology, Reproductive Endocrinology and Current Advances in Endocrinology Metabolism. Current Obesity Conferences 2020 has taken the start to assemble the world-class specialists both from industry and scholarly in a typical stage at Obesity Conferences.

The Organizing Committee spreads its welcome to 16th Euro Obesity and Endocrinology Congress during July 20-21, 2020 at Barcelona Spain with a theme “Fighting obesity with nutrition and innovative strategies”. Joining at Euro Obesity 2020 will provide an exceptional occasion to interact with world-class Obesity Specialists and Endocrinology Experts in the field creating a channel for collaborations and partnerships.